U.S. Stock Market Midday Update: Abbott Laboratories Surpasses Earnings Expectations, Rises 10.87%, Diagnostic Business Surge Drives Valuation Recovery

U.S. Stock Market Midday Update

Abbott Laboratories rose 10.87%, with increased trading volume. Based on recent key news:

1. On July 16, Abbott Laboratories reported second-quarter results that exceeded expectations, with revenue increasing 13% year-over-year to $12.59 billion, and adjusted earnings per share of $1.31, surpassing market expectations. The company raised its full-year adjusted earnings per share forecast to $5.45 to $5.60, driving the stock price up. Source: Titanium Media, Zhitong Finance

2. On July 16, Abbott Laboratories' diagnostics business saw a significant sales increase of 42%, becoming the main driver of performance growth. The company expects adjusted earnings per share for the third quarter to be between $1.38 and $1.46, with market expectations at $1.42. Source: Kegubao Report

3. On July 16, Abbott Laboratories raised its full-year profit forecast, expecting adjusted earnings per share to be between $5.45 and $5.60 in 2026, higher than previous forecasts. The company reaffirmed its expectation of comparable sales growth of 6.5% to 7.5% for the year. Source: AASTOCKS Medical devices and diagnostics business performed strongly, driving growth.

Stocks with High Trading Volume in the Industry

Intuitive Surgical rose 2.92%. Based on recent news,

1. On July 15, Intuitive Surgical was about to announce its second-quarter financial report, with analysts expecting earnings per share of $2.50, a year-over-year increase of 14.2%, and revenue expected to be $2.82 billion, a year-over-year increase of 15.6%. The market has high expectations for its performance, driving the stock price up.

2. On July 15, Bank of America Securities analyst Travis Steed maintained a buy rating on Intuitive Surgical, with a target price of $515. Analysts from Piper Sandler and Stifel Nicolaus also gave buy ratings, further boosting market confidence.

3. On July 15, HCA Healthcare lowered its full-year profit forecast, causing several stocks in the healthcare sector to decline, but Intuitive Surgical's stock price remained relatively strong due to its robust financial performance and market expectations. The medical device industry performed well overall, supported by macroeconomic data.

Boston Scientific rose 4.67%. Based on recent key news:

1. On July 15, Boston Scientific released strong second-quarter results, driving the stock price up. MarketBeat reported that although Boston Scientific currently holds a moderate buy rating among analysts, its performance provided new support for the stock price.

2. On July 14, Royal Bank of Canada and NEEDHAM lowered their target prices for Boston Scientific, causing the stock price to decline during trading. Royal Bank lowered its target price from $100 to $85, while NEEDHAM reduced its target price from $77 to $57, mainly due to the company's lowered guidance for 2026 On July 16, Boston Scientific, along with SpaceX and IBM, fell to a 52-week low due to concerns on Wall Street and profit-taking that led to a decline in stock prices. The market is cautious about the performance of technology stocks.

Medtronic rose 3.79%, with increased trading volume. Based on recent key news:

1. On July 16, Medtronic announced the completion of its acquisition of SPR Therapeutics for $650 million. This acquisition will incorporate SPR's FDA-approved SPRINT PNS system into Medtronic's product line, with limited expected impact on adjusted earnings per share in fiscal year 2027, transitioning to neutral to accretive thereafter. This news has bolstered market confidence in Medtronic's future growth, driving the stock price up.

2. On July 16, Medtronic announced a stock split for its Brazil BDR program, changing the ratio of BDRs to underlying shares from 1:2 to 1:8. Each shareholder holding 1 BDR will receive 3 additional BDRs on July 24, with record keeping on July 29. This move is seen by the market as a positive signal to increase liquidity and attract investors, further pushing the stock price higher.

3. On July 13, the U.S. FDA announced Medtronic's recall of the Harmony delivery catheter system due to the risk of the distal tip potentially detaching. Although this negative news could impact the company's reputation, the stock price still rose due to other positive news. Support for the biopharmaceutical industry has strengthened, and the market is active.

Stocks ranked among the top in industry market capitalization

Stryker rose 4.12%. Based on recent key news:

1. On July 15, AV-Comparatives released commercial security test results showing that Iranian hackers recently targeted Stryker with cyberattacks, highlighting the ongoing cybersecurity threat. This incident has raised market concerns about the company's security measures, which could affect investor confidence.

2. On July 15, competition in the robotic-assisted surgery market has intensified, with the influx of innovations and new products threatening Stryker's market share for the Mako system, particularly in high-margin consumable revenues. This market pressure could impact the company's future profitability.

3. On July 16, Stryker's annual report on hip, knee, and shoulder joint replacements showed positive long-term results for single-radius total knee arthroplasty, which may boost market confidence in the company's products. The medical device industry is facing increased competition, and cybersecurity risks need to be monitored